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Abstract
Purpose
To evaluate the role of germline SDHA mutation analysis by (1) comprehensive
literature review, (2) description of novel germline SDHA mutations and (3) in
silico structural prediction analysis of missense substitutions in SDHA.
Patients and methods
A systematic literature review and a retrospective review of the molecular and
clinical features of patients identified with putative germline variants in UK
molecular genetic laboratories was performed. To evaluate the molecular conse-
quences of SDHA missense variants, a novel model of the SDHA/B/C/D com-
plex was generated and the structural effects of missense substitutions identified
in the literature, our UK novel cohort and a further 32 “control missense vari-
ants” were predicted by the mCSM computational platform. These structural
predictions were correlated with the results of tumor studies and other bioin-
formatic predictions.
Results
Literature review revealed reports of 17 different germline SDHA variants in 47
affected individuals from 45 kindreds. A further 10 different variants in 15 pre-
viously unreported cases (seven novel variants in eight patients) were added
from our UK series. In silico structural prediction studies of 11 candidate mis-
sense germline mutations suggested that most (63.7%) would destabilize the
SDHA protomer, and that most (78.1%) rare SDHA missense variants present
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in a control data set (ESP6500) were also associated with impaired protein
stability.
Conclusion
The clinical spectrum of SDHA-associated neoplasia differs from that of germ-
line mutations in other SDH-subunits. The interpretation of the significance of
novel SDHA missense substitutions is challenging. We recommend that multi-
ple investigations (e.g. tumor studies, metabolomic profiling) should be per-
formed to aid classification of rare missense variants before genetic testing
results are used to influence clinical management.
Introduction
Phaeochromocytoma (PCC) is a catecholamine secreting
tumor arising from chromaffin tissue in the adrenal
medulla. Similar tumors arising from sympathetic ganglion
cells outside the adrenal are termed a paraganglioma (PGL)
and are to be distinguished from head and neck paragan-
gliomas (HNPGL), which are, in general, nonfunctional
tumors arising from parasympathetic ganglia (Boulpaep
et al. 2003). PCC/PGL are the most often inherited neu-
roendocrine tumors with approximately 40% of all cases
harboring a genetic mutation in one of at least 13 genes
(NF1, RET, VHL, SDHB, SDHC, SDHD, SDHA, SDHAF2,
MAX, TMEM127, HIF2A, MDH2) (Yang et al. 2015; Lor-
enzo et al. 2013; Burnichon et al. 2010; Qin et al. 2010; Hao
et al. 2009; Astuti et al. 2001a, 2001b; Baysal et al. 2000;
Niemann and M€uller 2000). In nonsyndromic cases of
PCC/PGL, germline mutations are most frequently identi-
fied in SDHB and SDHD (Jafri et al. 2013; Neumann et al.
2004; Gimenez-Roqueplo et al. 2003; Astuti et al. 2001a,b;
Baysal et al. 2000), which encode the B and D subunits of the
succinate dehydrogenase (SDH) complex (type II mitochon-
drial complex) which is an integral component of the citric
acid cycle (Oyedotun and Lemire 2004). SDH facilitates the
conversion of succinate to fumarate ensuring cellular meta-
bolism of lipids, glucose and amino acids, and feeds into the
mitochondrial respiratory chain to generate cellular energy
(Oyedotun and Lemire 2004). Mutations in SDHB and
SDHD have, in addition to PCC/PGL, also been associated
with predisposition to HNPGL, renal cell carcinoma (RCC),
gastrointestinal stromal tumors (GIST), and pituitary adeno-
mas (PA) (Pantaleo et al. 2013; Xekouki and Stratakis 2012;
Ricketts et al. 2010; Astuti et al. 2001a,b; Baysal et al. 2000).
The SDHD protein, together with SDHC, anchors the
SDH complex to the inner mitochondrial wall and binds to
SDHB, which in turn binds to SDHA (the catalytic subunit
of the complex) (Oyedotun and Lemire 2004). Alhough
mutations in SDHB, SDHC, and SDHD were associated with
inherited PCC/PGL/HNPGL and mutations in SDHA
were associated with autosomal recessive metabolic
encephalopathy syndrome (Leigh syndrome) about 15 years
ago (Horvath et al. 2006), the association of pathogenic
germline SDHA mutations with inherited PCC was
described only 5 years ago (Burnichon et al. 2012). In order
to better characterize the genetic and clinical features of
germline SDHA mutations, we undertook a literature
review, and analyzed the clinical and molecular features of
15 new cases that found to have a germline SDHA variant via
diagnostic testing and studied, computationally, the effect of
novel and previously reported SDHA missense variants on
SDHA structure. In addition, we assessed whether muta-
tions might be predicted to disrupt splicing (Di Gaicomo et
al. 2013; Woolfe et al. 2010; Wu and Hurst 2016; Pagani et
al. 2005; Soukarieh et al. 2016), either by disrupting splice
sites or by affecting exonic splice enhancers (Ke et al. 2011;
Caceres and Hurst 2013) or silencers (Ke at al. 2011).
Material and Methods
Case series
Details of rare potentially pathogenic germline SDHA
(OMIM: 600857, reference sequence: NG_012339.1) vari-
ants detected at UK NHS molecular diagnostic laborato-
ries were obtained from those undertaking genetic testing.
Referral data were collated on a standardized proforma
and included: gender, age at presentation, method of pre-
sentation (sporadic vs. familial), location of tumor, pres-
ence of bilateral/multifocal disease, and evidence of
malignancy. Malignancy was defined as the presence of
distant or local regional metastasis. Patients gave written
informed consent to a research ethics committee
approved research study and/or data was collected as part
of a molecular genetics service evaluation study.
Literature review
A SDHA mutation search in association with PCC/PGL,
GIST, RCC, PA, Leigh syndrome, and optic atrophy was
performed. This search was performed using the Human
Gene Mutation Database (www.hgmd.cf.ac.uk), the Leiden
Open Variation Database (http://www.lovd.nl/3.0/home),
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and publications indexed in PubMed (http://www.ncbi.nlm.
nih.gov/pubmed) up to May 2016. The following search
terms were used: SDHA mutation in combination with the
terms: phaeochromocytoma, paraganglioma, GIST, pituitary
adenoma, renal cell carcinoma, and the conditions Leigh syn-
drome and optic atrophy. Both germline and somatic variants
were included in the search and the results were subcate-
gorised for germline versus somatic variants identified.
Assessment of variant pathogenicity
In cases where the detected SDHA variant identified was
novel and suspected to be causative in the disease pheno-
type, classification of variant pathogenicity was performed
based on the recently published classification system by the
American College of Genomic Medicine (ACMG) (Richards
et al. 2015). This system categorizes variants as pathogenic
or benign. If a variant does not meet the criteria for either a
pathogenic or a benign variant, the recommendation is that
this variant be defaulted to a variant of uncertain signifi-
cance. Within the pathogenic category, variants can be fur-
ther subclassified as either; pathogenic or likely pathogenic.
Similarly within the benign category, sub classification
includes benign or likely benign (Richards et al. 2015).
The criteria used to classify a variant included; review of
the disease phenotype, the use of the predictive tools SIFT
and Poly-Phen2 and when available, review of functional
tumor studies (including immunohistochemical staining
(IHC) of the SDHB/SDHA protein and loss of heterozygos-
ity studies (LOH)). The presence of the disease allele in a
healthy control population was also confirmed by searching
the EXAC database (http://exac.broadinstitute.org/). Vari-
ants identified in the literature which, were not considered
to be disease causing by the authors were excluded.
Information from computational predictive tools above
and functional studies when available was combined with
in silico predicted changes in protein stability and protein-
protein affinity upon mutation for 18 missense variants
identified. This information was compiled and variants
were classified as per the ACMG recommendations. An
online genetic variation tool predictor (http://medschool.
umaryland.edu/Genetic Variant_Interpretation_Tool1.html)
based on ACMG guidelines was used to tabulate the evi-
dence for the 18 missense variants (see Table 2).
Modeling of the SDHA/B/C/D complex and
prediction of the effects of missense
substitutions
A molecular model of SDHA was generated using Modeller
and Macro Model (Schrodinger, New York, NY) using the
X-ray crystal structures of Succinate dehydrogenase flavo-
protein subunit from the Avian respiratory complex ii (92%
sequence identity; PDB ID: 1YQ4) (Huang et al. 2006) and
the Flavoprotein subunit of Complex ii from Ascaris suum
(72% sequence identity; PDB ID: 3VR8) (Shimizu et al.
2012). The models were then minimized using the MMF94s
forcefield in Sybyl-X 2.1.1 (Certara L.P, St Louis, MO, USA),
with the final structure having more than 95% of residues in
the allowed region of a Ramachandran plot. The FAD cofactor
and Succinate substrate were docked into the models using
Glide (Schrodinger), and the position of the ligands in avail-
able crystal structures used to guide placement. The quality of
the models was confirmed with Verify3D (data not shown).
Model structures were examined using Pymol. The model of
the succinate complex was built using our previously reported
models of SDHB and SDHD, with the X-ray crystal structure
of the Avian respiratory complex ii (PDB ID: 1YQ4) (Huang
et al. 2006) was used to guide protein docking.
The structural consequences of all the identified novel and
previously identified SDHA missense variants were analyzed
to account for all the potential effects of the mutations (Pires
et al. 2016). The effects of the mutations upon the stability of
SDHA were predicted using DUET (Pires et al. 2014a,b), an
integrated computational approach that optimizes the predic-
tion of two complementary methods (mCSM-Stability and
SDM). The effect of the mutations upon the protein–protein
binding affinity of SDHA to form the succinate complex were
predicted using mCSM-PPI (Pires et al. 2014a; Pires and
Ascher 2016). The effect of the mutations upon the binding
affinity of SDHA for the cofactor, FAD, and substrate, succi-
nate, were predicted using mCSM-Lig (Pires et al. 2015,
2016). These computational approaches represent the wild-
type residues structural and chemical environment of a resi-
due as a graph-based signature in order to determine the
change upon mutation in Gibb’s free energy of stability or
binding. To compare the in silico predictions for germline
SDHAmissense mutations detected in patients with those not
ascertained via diagnostic testing, we identified 24 rare (fre-
quency <0.01%) germline SDHAmissense variants present in
the ESP6500 cohort from Exome Variant Server (http://evs.gs.
washington.edu) and correlated the effect of these missense
variants on protein stability, complex formation, and ligand
binding using our in silico prediction approaches. In addition,
eight presumed missense somatic SDHA variants detected in
SDH-related tumor types (seven renal cell carcinomas and
one phaeochromocytoma) from the cBioPortal for cancer
genomics (http://www.cbioportal.org), were evaluated.
Modeling of mammalian alignment to
detect domains of purifying selection using
SDHA transcript
Mammalian alignment from the 100 vertebrate genomes
alignment for NM_004168.2 was downloaded via
Table Browser at UCSC https://genome.ucsc.edu/cgi-bin/
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hgTables. We calculated mean Ks (human to comparator)
and % gap in the alignment, and selected sequences with
<5% gap and <0.45 Ks (to avoid saturation problem) but
>0.1 Ks (to ensure adequate information). Baboon
sequence was eliminated owing to an in-frame stop. These
filters resulted in two human-primate comparators, these
being Human-marmoset (Callithrix jacchus, calJac3 assem-
bly) and human- bushbaby (Otelemur garnetti otoGar3
assembly). The two alignments were passed by package SLI-
DERKK.tcl (available form LDH) to calculate Ka/Ks ratios
in 108-bp windows. We employed Li93 as the method of
Ka/Ks calculation. We reviewed the variants identified in
this study to determine which variants plotted to domains
of strong purifying selection on this mammalian alignment.
Predicting the effects of the variants on
splice regulatory information
See Appendix S7.
Statistical analysis
Statistical tests were performed using SPSS. Student’s t-
test was used to compare continuous variables and
Mann–Whitney or an unpaired t-test to compare nonnor-
mally distributed data when sample numbers were small.
Summary statistics included means and standard devia-
tions for continuous variables, and frequencies and per-
centages for categorical variables.
Results
UK SDHA germline mutation series
Molecular genetics
Fifteen previously unreported patients with ten different
germline SDHA variants were identified (Table 1). Two
mutations had been reported previously: the common non-
sense mutation c.91C>T (p.Arg31*) was observed in five
patients and a c.1753C>T (p.Arg585Trp) missense mutation
in one patient. A novel truncating mutation in c.1468G>T
(p.Glu490*) was identified in one patient with a metastatic
GIST tumor. Four further novel candidate missense vari-
ants, one frameshift variant and one splice acceptor variant
were detected in six kindreds (see Table 1) (a novel missense
variant, c.923C>T (p.Thr308Met) in exon 8 of SDHA was
detected in two apparently unrelated patients).
Clinical features
Four patients presented with a GIST and eleven patients
presented with a PCC/PGL. The mean age of disease
presentation was 37.1 years (SD 14.2) with a range of 12–
65 years. None of the affected individuals had a family
history of SDH-related tumors. One proband with a trun-
cating SDHA mutation (c.91C>T p.Arg31*) had a first
degree relative tested after diagnosis who is an asymp-
tomatic mutation carrier at age 72 years. One patient had
died from another disease process at the time of this
review. One patient with the c.923C>T (p.Thr308Met)
missense variant was diagnosed with a malignant medi-
astinal paraganglioma at age 43 years and the second
patient presented at a later age (52 years) with multiple
bilateral HNPGL and a unilateral PCC. Further unre-
ported variants included a missense variant in c.1273G>A
(p.Val425Met) in a 62-year- old gentleman presenting
with a para-spinal PGL and unilateral PC, two further
missense mutations; c.133G>A (p.Ala45Thr) in exon 2 in
a young male with a mediastinal PGL and c.136A>G
(p.Lys46Glu) in exon 2, which was detected in a girl pre-
senting of age 12 with a porta hepatis PGL. A novel trun-
cating mutation [c.1468G>T (p.Glu490*)] was identified
in a male patient, who presented aged 32 years with a
GIST and later aged 36 and 38 years developed liver and
lung metastases. The final two novel variants detected
included a frameshift mutation (c.1338delA) in a 48-year-
old female with a HNPGL and a splice mutation (c.1909-
2A>G) in a 31-year-old female with a GIST.
Literature review of germline and somatic
SDHA mutations
Germline SDHA mutations
Of 17 unique germline SDHA variants were identified in
47 individuals from 45 kindreds (Table S1). Three recur-
rent germline variants were identified: c.91C>T (p.Arg31*)
nonsense variant in 22 kindreds (23 affected individuals)
and two missense variants: c.1753C>T (p.Arg585Trp) (in
two kindreds and two affected individuals) and c.1765C>T
(p.Arg589Trp) (in four kindreds and four affected individ-
uals). Details of clinical phenotype (Table S1) revealed that
the most common association was with GIST tumors
(mean age at diagnosis 33.4 years (SD+11.1), range 17–
62 years) occurring in 31 of the 47 affected individuals.
Five reported cases of metastatic GIST with SDHA germ-
line variants were identified: two cases in association with
a c.91C>T (p.Arg31*) (Pantaleo et al. 2011a,b; Italiano
et al. 2012) and three further cases of metastatic GIST
have been published in patients with the following muta-
tions in SDHA: c.1151C>G (p.Ser384*) (Pantaleo et al.
2011a,b), c.1765C>T (p.Arg589Trp) (Wagner et al. 2013),
and c.1534C>T (p.Arg512*) (Wagner et al. 2013) Reports
of the PCC/PGL phenotype included eight PGL (abdomi-
nal or thorax), four HNPGL, and one PCC. There were
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two reports of malignant PCC/PGL in association with
germline SDHA variants. One patient with a sympathetic
bladder PGL and a c.91C>T (p.Arg31*) variant (Burni-
chon et al. 2012), and a second patient with a HNPGL
and a c.1534C>T (p.Arg512*) variant (Papathomas et al.
2015). No case of multifocal PCC/PGL was identified. One
report of nonfunctioning pituitary marcoadenoma and a
germline SDHA variant was identified (Dwight et al.
2013a). Three recent case reports of renal cell carcinoma
(RCC) in association with a SDHA variant have been pub-
lished (Jiang et al. 2015; Ozluk et al. 2015; Yakirevich
et al. 2015). One patient had a novel germline variant in
c.2T>C (p.M1T) in the initiation codon of SDHA (Jiang
et al. 2015) and was diagnosed with a renal cell chromo-
phobe tumor and a multifocal GIST tumor. The two fur-
ther reports were associated with somatic mutations and
are described below.
An incomplete penetrance pattern with SDHA muta-
tions is suggested by the sparse number of familial
cases identified. Only two familial SDHA mutations
were reported: two sisters with a c.91C>T (p.Arg31*)
variant and GIST (Oudijk et al. 2013) and an addi-
tional family with a c.1873C>T (p.His625Tyr) variant,
where the mother was the proband and had a HNPGL
and her son had a nonfunctioning PA (Dwight et al.
2013b). The characteristics and population frequency of
individual SDHA mutations described in the literature
are described in Tables S1 and S2. The recurrent
c.91C>T (p.Arg31*) nonsense mutation is recorded as
occurring in 0.2 per 1000 individuals in the EXAC
database (exac.broadinstitute.org/about) and all except
one of the putative germline variants in our UK series
and in the literature had a frequency of <1 per 1000
individuals in the EXAC dataset. However, a c.113A>T
(p.Asp38Val) missense substitution described (Italiano
et al. 2012) as a somatic mutation in a 26-year-old fe-
male with a metastatic GIST tumor with liver and peri-
toneal metastasis was present in 3.5% of individuals in
the EXAC database.
A total of nine germline variants (three missense, six
truncating) in SDHA, associated with either optic atrophy
or Leigh syndrome were identified in the literature
(Table S3). The only germline variant associated with
both Leigh syndrome/optic atrophy and tumorigenesis
including GIST and PCC/PGL was the c.91C>T
(p.Arg31*) truncating variant.
Somatic SDHA mutations
Eleven cases of somatic candidate SDHA mutations were
identified in the literature (Table S1): seven missense vari-
ants and four truncating. The associated tumor types
included: GIST (n = 8), RCC (n = 2) and PA (n = 1).
Two cases of RCC are associated with somatic SDHA vari-
ants (Ozluk et al. 2015; Yakirevich et al. 2015) and had
histologic features, which were consistent with the histol-
ogy typically associated with SDHB associated RCC (Ozluk
et al. 2015; Yakirevich et al. 2015). One patient with a
novel somatic 17 kbp SDHA homozygous deletion on
chromosome 5p15, had malignant RCC (Yakirevich et al.
2015).
In silico structural analysis of germline and
somatic SDHA variants associated with
tumorigenesis
Computational approaches were employed to assess
the effects of mutations on protomer stability, complex
Table 1. Clinical phenotype of patients with variants in SDHA in novel UK cohort.
Mutation Sex Age Category Single/multiple Secretory Malignant
c.91C>T (p.Arg31*) M 56 HNPGL Single No No
c.91C>T (p.Arg31*) M 33 Abdominal PGL Single N/A No
c.91C>T (p.Arg31*) M 45 Abdominal PGL Single Yes No
c.91C>T (p.Arg31*) F 15 Adrenal PCC Single Yes No
c.91C>T (p.Arg31*) M 35 GIST Single No Yes
c.133G>A (p.Ala45Thr) M 36 Thoracic PGL Single No No
c.136A>G (p.Lys46Glu) F 12 Abdominal PGL Single Yes No
c.923C>T (p.Thr308Met) F 43 Thoracic PGL Single Yes Yes
c.923C>T (p.Thr308Met) M 52 HNPGL Multiple Yes No
c.1273G>A (p.Val425Met) M 62 PC and Paraspinal PGL. Multiple Yes No
c.1338delA (p.His447Metfs*23) F 48 HNPGL Single No No
c.1468G>T (p.Glu490Ter) M 32 GIST Single No Yes
c.1753C>T (p.Arg585Trp) F 34 PGL Single No No
c.1765C>T (p.Arg589Trp) F 42 GIST Single No No
c.1909-2A>G F 31 GIST Single No No
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formation and ligand binding to classify all identified
SDHA missense variants associated with tumorigenesis
in the literature and our unpublished cohort. A total
of 18 putative missense mutations (11 germline and
seven somatic) were analyzed. The data obtained from
this in silico analysis were compiled with other predic-
tive tools and a classification of these missense vari-
ants was made based on the ACMG recommendations
(Richards et al. 2015) from the existing criteria avail-
able on each variant.
The mean DUET stability score was 0.52 kcal/mol
(SD 0.936) for the 18 missense variants associated with
tumorigenesis (mean 0.53 kcal/mol for 11 germline
variants and 0.48 kcal/mol for seven somatic variants.
The mean DUET score for missense variants (n = 3)
reported in association with Leigh syndrome/optic atro-
phy was 1.15 kcal/mol.
The most destabilizing germline mutation predicted by
DUET was 1.81 kcal/mol and associated with the mis-
sense variant c.1766G>A (p.Arg589Gln). This missense
variant was detected in a single case of GIST in the liter-
ature. The second highest DUET score was associated
with the germline missense variant c.1765C>T
(p.Arg589Trp) which was identified in one patient in
our study cohort with a GIST, and has been identified
in the literature in one other patient with GIST and two
patients with paragangliomas (see Table 3). Overall the
most destabilizing mutation predicted by DUET was
3.1 kcal/mol and associated with a somatic mutation
(c.1361C>A p.Ala454Glu) identified in a single case of
GIST in the literature (see Table S1). Interestingly this
variant was associated with loss of SDHB staining on
immunohistochemistry but retained SDHA staining. This
in silico prediction tool, predicted that the variant was
highly destabilizing. It is in the FAD binding pocket and
the mutation would abolish FAD binding and disrupt
formation of the succinate complex.
The variant c.923C>T (p.Thr308Met) identified in two
unrelated patients in our cohort with aggressive pheno-
types (see Table 1) was predicted to mildly destabilize
the protein protomer and part of substrate binding with
a DUET score of 0.498 kcal/mol. No significant differ-
ences were detected between DUET scores of missense
variants associated with GIST and with PCC/PGL
(P = 0.2).
The in silico prediction tool predicted that 8/18 mis-
sense variants analyzed would have a mild or no effect
on protein stability. Two of the eight variants were
somatic variants; c.113A>T (p.Asp38Val) identified in a
single GIST in the literature and the c.1334C>T
(p.Ser445Leu) variant, also detected in a single GIST in
the literature. The remaining six variants were germline
and four of the six variants were identified in our novel
UK cohort; c.133G>A (p.Ala45Thr), c.136A>G (p.Lys46-
Glu), c.923 C>T (p. Thr308Met), c. 1273G>A (p.Val425-
Met). A potential alternative mechanism for
pathogenicity could be postulated for three N-terminal
missense substitutions: c.113A>T (p.Asp38Val),
c.133G>A (p.Ala45Thr) and c.136A>G (p.Lys46Glu),
which were predicted to affect the transit peptide and
potentially alter protein localization (see Table 3). One
variant, c.1690G>A (p.Glu564Lys), was predicted to
destabilize complex formation by mCSM-PPI (score of
0.951 kcal/mol).
A total of 8 somatic missense SDHA variants were
identified from the cBioportal (http://www.cbioportal.org)
in tumors associated with the SDHA disease phenotype.
The mean DUET score in this group was 0.94 kcal/mol
and 75% (6/8) of the missense variants were predicted to
destabilize the protein or its ability to bind the substrate
or form a complex (see Table S5). Three of these muta-
tions were also predicted to affect complex formation (av-
erage mCSM-PPI score of 1.025 kcal/mol).
In silico structural analysis of germline
SDHA variants in control dataset
If SDHA pathogenic variants are usually associated with
a low penetrance phenotype it might be postulated that
rare pathogenic variants might also be detected in the
general population. We therefore analyzed 24 rare
(<0.05%) missense variants reported in a control data
set (EVS6500, http://evs.gs.washington.edu) but not pre-
sent in patient cohorts (Table S4) for predicted effect on
protein stability, protein–protein and protein–ligand
affinity and found that most 75% (18/24) were predicted
to have a destabilizing effect and 41.6% (10/24) were
predicted to affect complex formation. The in silico pre-
dictions of DUET correlated with SIFT and Polyphen
prediction tools for 58.3% (14/24) of the variants. Addi-
tionally, 75% (6/8) of the somatic missense variants
identified in RCC and 1 PCC tumor described in the
CBioportal database were predicted to destabilize the
protein (7/8) were predicted to be deleterious by SIFT/
Polyphen) (see Table S5).
Tumor analysis in UK cohort
Two tumor specimens from our unpublished cohort were
available for analysis. SDHA sequence analysis on a PGL
from a patient with a c.1753 C>T variant (p.Arg585Trp)
demonstrated partial loss of the wild-type allele in the
tumor DNA consistent with pathogenicity. Tumor tissue
from a patients with a c.91C>T (p.Arg31*) confirmed the
presence of the variant but no loss of the wild type allele
was detected (data not shown).
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Classification of potential pathogenicity of
germline SDHA variants associated with
disease in our cohort and literature
Data from the in silico protein stability and affinity pre-
dictions was collated with data from computational pre-
dictive analyses and tumor studies in order to classify 18
identified missense variants as per the ACMG guidelines
(Richards et al. 2015). 13/18 (72.2%) missense variants
met the criteria for a pathogenic (or likely pathogenic)
mutation (see Table 2). Five variants (29.5%) did not
meet the criteria for a pathogenic mutation, and the sup-
porting evidence was supportive of a likely benign variant
for four variants and one variant was classified as a vari-
ant of uncertain significance (VUS) because of insufficient
evidence to classify as benign or pathogenic.
The five variants included four novel variants identified
in our UK cohort and one variant identified from the liter-
ature. The first variant c.113A>T (p.Asp38Val), was a
somatic variant and identified from the literature in a
patient with a metastatic GIST. This variant was predicted
to be benign by SIFT and Polyphen 2 prediction and is fre-
quently seen in healthy controls (2.1%). It was predicted to
cause potential disruption to the transit peptide on our in
silico structural analysis and tumor analysis was reported
to show loss of heterozygosity and loss of SDHA immunos-
taining (one limitation to this study was only three SDHA
exons were sequenced and another undetected mutation
might have been present in cis) (Italiano et al. 2012).
Interestingly the variant c.1873C>T (p.His625Tyr), clas-
sified as likely pathogenic as per ACMG (Richards et al.
2015), was not shown to have any effect on protein
stability in our in silico analysis (Table 3). This variant
was identified in a patient with a PGL (proband) and her
son who was diagnosed with a pituitary adenoma
(Dwight et al. 2013a). No loss of the wild type allele was
demonstrated in the pituitary adenoma but loss of SDHA
and SDHB immunostaining was demonstrated in both
tumor types. Taking a closer look at this mutation at a
molecular level, however, reveals that His625 establishes
an intricate network of polar interactions, including ionic
interaction with Asp135 and Asp289, a donor–pi interac-
tion with a Gln288 and a main-chain to main-chain
hydrogen bond with Arg642 (depicted in Fig. 1). These
would most likely be disrupted by the mutation to Tyr,
destabilizing the protein.
The three remaining variants classified as likely benign
and the variant classified as a VUS were identified in our
novel cohort. One limiting factor to this classification was
that tumor tissue was not available and so the variants
could not be fully assessed. The first two variants
c.133G>A (p.Ala45Thr) detected in a patient with a tho-
racic PGL and the c.136A>G (p.Lys46Glu), identified in a
patient with an abdominal PGL, were consistently pre-
dicted as benign variants across different computational
analysis tools and occurred at a frequency of up to 0.03%
in healthy controls (see Table 1). These variants were pre-
dicted as having a potential effect on the transit peptide
but the DUET, mCSM-PPI and mCSM-Lig scores could
not be calculated and there was no effect on the cofactor.
The remaining variants were suspected to be pathogenic.
The first variant c.923C>T (p.Thr308Met), was detected in
two patients who are not known to be related. This variant
was associated with a malignant mediastinal PGL in one
Table 2. Classification of potential pathogenicity of SDHA missense variants identified in literature and novel UK cohort as per ACMG guidelines
Variant Effect Evidence
c.113A>T (p.Asp38Val) Likely benign (II) PP5, PP4, BP1, BP4, BS1
c.133G>A (p.Ala45Thr) Likely benign (II) PP4, BP1, BP4, PS3
c.136A>G (p.Lys46Glu) Likely benign (II) PP4, BP1, BP4
c.511C>T (p.Arg171Cys) Likely pathogenic (III) PS3, PP4, BP1, PP3
c.562C>T (p.Arg188Trp) Likely pathogenic (III) PS3, PP3, PP4, BP1
c.767C>T (p.Thr256Ile) Likely pathogenic (III) PS3, PP3, PP4, BP1
c.800C>T (p.Thr267Met) Likely pathogenic (III) PS3, PP3, PP4, BP1
c.923C>T (p.Thr308Met) VUS - not enough
evidence
BP1, PP3
c.1255G>A (p.Gly419Arg) Likely pathogenic (III) PP4, PP3, PS3, BP1
c.1273G>A (p.Val425Met) Likely benign (II) BP1, PP4, BP4
c.1334C>T (p.Ser445Leu) Likely pathogenic (III) BP1, PP3, PS3, PP4
c.1361C>A (p.Ala454Glu) Likely pathogenic (III) PS3, PP3, PP4, PP5
c.1690G>A (p.Glu564Lys) Likely pathogenic (III) PS3, PP4, PP3, BP1
c.1753C>T (p.Arg585Trp) Likely pathogenic (III) PS3, PP3, PP4, BP1
c.1765C>T (p.Arg589Trp) Likely pathogenic (III) PS3, PP5, PP3, PP4, BP1
c.1766G>A (p.Arg589Gln) Likely pathogenic (III) PS3, PP4, PP5, PP3, BP1
c.1794G>C (p.Lys598Asn) Likely pathogenic (III) PS3, PP3, PP4, PP5, BP1
c.1873C>T (p.His625Tyr) Likely pathogenic (III) PS3, PP3, PP4, PP5, BP1
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patient and multiple PGL and a PCC in a second patient.
This variant was predicted to be benign by SIFT and Poly-
Phen but has not been identified in healthy controls and
was also found to mildly destabilize the protomer and sub-
strate binding site and therefore is likely to affect protein
stability. Thr308 establishes, apart from hydrophobic inter-
actions, hydrogen bonds that would be lost by the substitu-
tion to Methionine, which could also induce steric clashes
(Fig. 2). Its proximity to the ligand FAD, could also imply
a change in substrate binding as well. However due to
insufficient evidence, the default classification of this vari-
ant was VUS. The final variant c.1273G>A (p.Val425Met),
was detected in a patient with a spinal PGL and PCC. This
variant was predicted to be pathogenic by SIFT and Poly-
Phen and is only present in .002% of healthy controls.
However this variant was not found to impact on protein
stability by our in silico prediction analysis. As functional
studies were not performed on this variant the overall crite-
ria for a likely pathogenic variant were not met and the
classification was a likely benign variant as per ACMG (see
Table 2).
Prediction of splice disruption
Appendix S7.
Variants plotted to domains of strong
purifying selection on mammalian
alignment
A priori we might expect disease causing mutations to be
more common in domains of high-conservation within a
gene, although disruption of such domains can also result
in early embryonic mortality and so not be considered
pathogenic. Calculation of SDHA Ka/Ks ratios for human
versus marmoset (Callithrix jacchus, calJac3 assembly) and
bushbaby (Otelemur garnetti otoGar3 assembly) revealed
evidence for domains of strong purifying selection (Ka/Ks
< 0.1) across multiple spans of the gene (Fig. 3). A total
of 29.4% (n = 5/17) of the analyzed SDHA missense vari-
ants mapped to domains of strong purifying selection
and 46% (n = 11/24) missense variants identified in
healthy controls (see Table S6) (frequency <0.01%) (from
Exome Variant Server (http://evs.gs.washington.edu).
These frequencies are not significantly different (chi
squared = 0.21, P = 0.88).
Discussion
To date, germline mutation analysis of SDHA has not
been widely adopted in clinical practice. In part this
relates to the more recent (compared to SDHB/C/D)
Figure 2. Molecular depiction of the effect on protein caused by
c.923C>T (P.Thr308Met) SDHA mutation.
Figure 3. Modeling of mammalian alignment to detect domains of
purifying selection using SDHA transcript.
Figure 1. Molecular depiction of the effect on protein caused by
c.1873C>T (p.His625Tyr) SDHA mutation.
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association of SDHA mutations with tumorigenesis (Pan-
taleo et al. 2011a, 2011b; Burnichon et al. 2010; Dwight
et al. 2013b; Jiang et al. 2015), but also to technical chal-
lenges (molecular genetic analysis of SDHA is complicated
by its four known pseudogenes, generated by complete or
partial gene duplications (Rattenberry et al. 2013).
Alhough the SDHA/B/C/D subunits form a single com-
plex, mutations in different genes are associated with rela-
tive differences in susceptibility to specific tumor types.
Thus, whilst SDHA is often not tested routinely for in
PCC/PGL/HNPGL cases, it does appear to be a much
rarer cause of PCC/PGL/HNPGL than SDHB and SDHD
mutations. However, though other mutations in other
SDH subunit genes may also be associated with GIST, the
relative frequency of SDHA mutations reported in associ-
ation with GIST appears much higher than other subunits
(Boikos et al. 2016). Interestingly, SDHA-associated GIST,
has been reported to occur at an older age and have less
female preponderance (Miettinen and Lasota 2014). Nev-
ertheless, the tumorigenic effects of SDHA mutations are
thought to be mediated through similar mechanisms as
for mutations in other SDH subunits e.g. through a pseu-
dohypoxic drive, facilitating angiogenesis and aberrant cell
proliferation (Lopez-Jimenez et al. 2010) and epigenetic
effects through the accumulation of succinate, and subse-
quent inhibition of demethylase enzymes resulting in pro-
moter hypermethylation and tumor suppressor gene
inactivation (Letouze et al. 2013).
Since SDHA mutations were initially associated with
PCC/PGL the spectrum of associated tumors has
expanded to also include HNPGL, GIST, renal tumors,
and pituitary adenoma (PA) (Pantaleo et al. 2011a,
2011b; Burnichon et al. 2010; Dwight et al. 2013b; Jiang
et al. 2015). Thus the detection of a rare putative SDHA
mutation might have clinical significance. However,
SDHA mutations appear to have reduced penetrance
(multiple affected individuals within a single family are
rare) and SDHA mutations (e.g. c.91C>T p.Arg31*) can
occur in healthy individuals at a population frequency of
between 1/1000 and 1/10,000 (see Table 2). Thus the
interpretation of the contribution of a putative novel
germline SDHA mutation to the observed phenotype may
not be straightforward as familial segregation studies are
unlikely to be informative and the presence of the variant
in control populations does not exclude pathogenicity.
Interestingly a high variant density has been identified for
SDHA in African American samples (Baysal et al. 2007).
This increased variant expression was initially attributed
to higher rates of gene recombination, however a study
using a high resolution recombination map have disputed
this theory as a low recombination rate at the locus of
the SDHA gene was observed (Myers et al. 2005). It is
now considered more likely that the four known SDHA
pseudogenes have contributed to increased SDHA variant
density by illegitimate recombination or gene conversion
at the time of meiosis.
Bioinformatic prediction tools such as Polyphen and
SIFT are widely used to aid the interpretation of the likely
pathogenicity of sequence variants, although it is well rec-
ognized that they have their limitations. Previously, we
and others have found that in silico structural prediction
analysis tools can aid the classification of germline SDHB
and SDHD variants (Ricketts et al. 2010). Although we
found that most putative SDHA mutations detected in
patients presenting with a relevant tumor were reported
to impair protein stability, we also found that many rare
SDHA missense variants present in the ESP6500 exome
sequencing data set were also predicted to be destabilizing
by DUET and pathogenic by PolyPhen/SIFT. Though no
information is available on the phenotype of ESP6500
individuals with SDHA variants, this comparison does
illustrate the challenge in interpreting the significance of
rare genetic variants in candidate genes.
Identification of rare genetic variants associated with
inherited tumor predisposition can enable testing of at
risk relatives (and appropriate surveillance of mutation
carriers), enhanced surveillance (if they are at increased
risk of second primary tumors) and, if applicable, tar-
geted therapy for the affected individual. In the case of
putative SDHA mutations, the evidence for incomplete
penetrance and lack of information on tumor risks in
non-probands suggests that the genetic testing and inten-
sive surveillance of at risk family members will generally
not be indicated until more information on the genetic
epidemiology and age-related tumor risks are available.
For affected individuals with putative missense mutations,
we suggest that, in addition to in silico protein structure
and bioinformatic predictions of pathogenicity (e.g. SIFT/
PolyPhen), additional studies should be undertaken to aid
variant classification. Loss of heterozygosity (LOH) analy-
sis of tumors can support a case for pathogenicity if there
is loss of the wild type allele. Though the absence of LOH
does not exclude pathogenicity of the variant as other
mechanisms such as somatic point mutations or pro-
moter hypermethylation can inactivate the wild-type allele
without causing LOH (as seen in our case with a c.91
C>T (p.Arg31*) variant and reported by others (Lussey-
Lepoutre et al. 2015). Tumor immunohistochemistry
(IHC) can also support pathogenicity by demonstrating
the loss of SDHA expression (Miettinen et al. 2013).
However discrepancies between IHC results and predicted
pathogenicity of SDH gene variants, appear to be more
common for SDHA variants identified in patients with
GIST (Evenepoel et al. 2015).
Furthermore, we suggest that there should also be an
increased emphasis on defining whether a rare germline
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SDHA variant is associated with the expected functional
consequences of SDHA inactivation in the relevant tumor.
Thus metabolomic analysis using in vivo MRI spec-
troscopy (MRS) or in vitro high resolution magic angle
spinning (HRMAS), have recently been reported as useful
diagnostic adjunct in patients with putative SDHX gene
mutations. Peaks in the metabolite succinate in tumor tis-
sue as a result of a defective succinate dehydrogenase
enzyme, have been demonstrated as a sensitive and speci-
fic hallmark of SDH mutations (Imperiale et al. 2015;
Lussey-Lepoutre et al. 2015) and have been described in
an abdominal PGL associated with a germline SDHA
c.91C>T (p.Arg31*) mutation (Lussey-Lepoutre et al.
2015). Similarly, methylome profiling can be used to
identify the hypermethylation epigenetic alterations asso-
ciated with SDHx inactivation (Letouze et al. 2013). The
correct classification of putative SDHA mutations and the
demonstration of the expected abnormal tumor meta-
bolic/epigenetic profile will become increasingly impor-
tant as targeted therapies based on derangements in the
metabolic/epigenetic abnormalities are developed and
studied.
In conclusion, this review of published SDHA muta-
tions and reporting of variants from our novel cohort,
should aid interpretation of genetic testing results in
patients with relevant tumor types. We advise that
caution should be exercised in interpreting pathogenic-
ity of novel rare sequence variants and that, in such
cases, whenever possible a variety of strategies, includ-
ing structural prediction analysis and molecular genet-
ics, SDHB/SDHA immunohistochemical analysis,
metabolomic and methylome profiling of tumors
should be performed, to better define the likelihood of
pathogenicity of SDHA variants to ensure optimum
clinical management.
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Supporting Information
Additional Supporting Information may be found online
in the supporting information tab for this article:
Appendix S1. Methods and Results.
Table S1. SDHA variants (both germline and somatic)
described in literature.
Table S2. Characteristics of pathogenic variants reported
in the literature.
Table S3. Variants associated with optic atrophy or Leigh
syndrome.
Table S4. SDHA variants identified from EVS not associ-
ated with disease in our cohort or Literature.
Table S5. SDHA variants identified as somatic mutations
in related tumor types in CBioportal.
Table S6. Variants that mapped to domains of strong
purifying selection on mammalian alignment.
Table S7. Predicted effects of mutations on splicing. To
determine the effect of exonic mutations on splicing we
considered both whether they were at splice sites (dis-
tance = 0 – light green highlight) and whether they were
predicted to have a significant effect on the density of
exonic splice enhancers and suppressors. The change in
exonic splice regulation score is given in column 3, with
a Z score and P value (from simulation) in columns 4
and 5. A negative Z score is considered as a prediction of
disrupted splicing. Mutations predicted to disrupt exonic
splice enhancer motifs at P < 0.05 are shown in yellow.
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